This may be due to increased activation of SREBP2, the principal activator for HMGCR, which seems specific for NAFLD patients as it was not shown in weight-matched obese or hepatitis C patients as controls [28]. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.